Maximizing geographic and scientific reach through a Northern California APOLLO Network: application for Clinical Center,
Role: PD/PI,
University of California, San Francisco,
(09/2023 - 05/2024)
Status: Awarded
Maximizing geographic and scientific reach through a Northern California APOLLO Network: application for Clinical Center,
Role: PD/PI,
University of California, San Francisco,
(06/2020 - 07/2023)
Status: Closed
For Profit Organization
ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study),
Role: Investigator,
Atara Biotherapeutics, Inc.,
(12/2024 - 12/2025)
Status: Approved
Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR),
Role: PI,
CareDx, Inc.,
(10/2024 - 10/2025)
Status: Approved
A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants,
Role: Investigator,
Medeor Therapeutics, Inc.,
(05/2023 - 04/2024)
Status: Completed
A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(02/2018 - 02/2019)
Status: Completed
A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015),
Role: Investigator,
Oxford Immunotec,
(07/2017 - 07/2018)
Status: Completed
(CDA) ExThera Medical Corp / Dr. Rafael Villicana,
Role: PD/PI,
ExThera Medical Corporation,
Status: Awarded
Internal
The role of B cells in kidney allograft dysfunction (B cell 3/1/2014),
Role: Investigator,
LLU Transplantation Institute,
(06/2022 - 06/2023)
Status: Completed
Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation,
Role: Investigator,
LLU Dept. of Surgery,
(10/2020)
Status: Approved
Incidence of Glomerular Disease Post-Kidney Transplant,
Role: Investigator,
LLU Dept. of Medicine,
(10/2024)
Status: Approved
Non-Profit Organization
Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation,
Role: Investigator,
American Society of Transplant Surgeons,
(08/2024 - 08/2025)
Status: Approved